类风湿关节炎中与甲氨蝶呤治疗应答相关的细胞特异性差异DNA甲基化鉴定
研究纳入类风湿关节炎患者(类风湿关节炎药物研究n=66,加州大学旧金山分校类风湿关节炎研究n=11),在甲氨蝶呤治疗前后采集全血,用Illumina芯片和Tensor Composition Analysis分析细胞特异性DNA甲基化与EULAR应答的关系。发现治疗应答组间存在整体甲基化差异,CD4+ T细胞、CD8+ T细胞和自然杀伤细胞中各有1个差异甲基化位点与基线应答相关,并鉴定出39个细胞特异性差异甲基化区域;全血样本分析无显著发现。
要点
- CD4+ T细胞、CD8+ T细胞和自然杀伤细胞中各鉴定出1个与甲氨蝶呤应答相关的基线差异甲基化位点。
- 共鉴定出39个与甲氨蝶呤治疗应答相关的细胞特异性差异甲基化区域。
- 全血样本分析未发现显著结果,提示需分选细胞检测DNA甲基化。
核心结论
- 在类风湿关节炎患者中鉴定出与甲氨蝶呤治疗应答相关的细胞特异性DNA甲基化改变。
- 作者认为未来关于DNA甲基化与甲氨蝶呤治疗应答的研究应包括分选细胞的DNA甲基化检测。
研究设计与样本
- 研究纳入类风湿关节炎药物研究66例和加州大学旧金山分校类风湿关节炎研究11例患者,均符合美国风湿病学会类风湿关节炎分类标准。
- 在基线和甲氨蝶呤治疗3-6个月后采集全血,用Illumina Infinium HumanMethylation450和MethylationEPIC v1.0 BeadChip芯片生成甲基化谱。
- 甲氨蝶呤应答按EULAR应答标准定义:应答者为良好或中度应答,无应答者为无应答。
- 用Limma软件包和Tensor Composition Analysis鉴定差异甲基化位点,用Comb-p软件鉴定差异甲基化区域。
主要发现
- 发现治疗应答组之间存在整体甲基化差异的证据。
- 发现与甲氨蝶呤应答相关的细胞特异性整体甲基化差异模式。
- 多重检验校正后,基线时CD4+ T细胞、CD8+ T细胞和自然杀伤细胞中各有1个差异甲基化位点与应答者和无应答者之间的DNA甲基化差异相关。
- 鉴定出39个与甲氨蝶呤治疗应答相关的细胞特异性差异甲基化区域。
- 全血样本分析中无显著发现。
关键数值与推荐
- 甲氨蝶呤应答定义采用EULAR应答标准:应答者为良好或中度应答,无应答者为无应答。
- 多重检验校正后,CD4+ T细胞、CD8+ T细胞和自然杀伤细胞中各1个差异甲基化位点与基线DNA甲基化差异相关。
- 共鉴定39个细胞特异性差异甲基化区域与甲氨蝶呤治疗应答相关。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: We undertook this study to estimate changes in cell-specific DNA methylation (DNAm) associated with methotrexate (MTX) response using whole blood samples collected from rheumatoid arthritis (RA) patients before and after initiation of MTX treatment. METHODS: Patients included in this study were from the Rheumatoid Arthritis Medication Study (n = 66) and the University of California San Francisco Rheumatoid Arthritis study (n = 11). All patients met the American College of Rheumatology RA classification criteria. Blood samples were collected at baseline and following treatment. Disease Activity Scores in 28 joints using the C-reactive protein level were collected at baseline and after 3-6 months of treatment with MTX. Methylation profiles were generated using the Illumina Infinium HumanMethylation450 and MethylationEPIC v1.0 BeadChip arrays using DNA from whole blood. MTX response was defined using the EULAR response criteria (responders showed good/moderate response; nonresponders showed no response). Differentially methylated positions were identified using the Limma software package and Tensor Composition Analysis, which is a method for identifying cell-specific differential DNAm at the CpG level from tissue-level ("bulk") data. Differentially methylated regions were identified using Comb-p software. RESULTS: We found evidence of differential global methylation between treatment response groups. Further, we found patterns of cell-specific differential global methylation associated with MTX response. After correction for multiple testing, 1 differentially methylated position was associated with differential DNAm between responders and nonresponders at baseline in CD4+ T cells, CD8+ T cells, and natural killer cells. Thirty-nine cell-specific differentially methylated regions associated with MTX treatment response were identified. There were no significant findings in analyses of whole blood samples. CONCLUSION: We identified cell-specific changes in DNAm that were associated with MTX treatment response in RA patients. Future studies of DNAm and MTX treatment response should include measurements of DNAm from sorted cells.
引用
- Adams C, Nair N, Plant D, et al. Identification of Cell-Specific Differential DNA Methylation Associated With Methotrexate Treatment Response in Rheumatoid Arthritis. Arthritis Rheumatol. 2023. PMID: 36716083. doi:10.1002/art.42464
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。